Rolla, S., De Mercanti, S. F., Bardina, V., Horakova, D., Habek, M., Adamec, I. ... Clerico, M. (2017). Lack of CD4 + T cell percent decrease in alemtuzumab-treated multiple sclerosis patients with persistent relapses. Journal of Neuroimmunology, 313., 89-91. doi: 10.1016/j.jneuroim.2017.10.009
Rolla, Simona, et al. "Lack of CD4 + T cell percent decrease in alemtuzumab-treated multiple sclerosis patients with persistent relapses." Journal of Neuroimmunology, vol. 313, 2017, str. 89-91. https://doi.org/10.1016/j.jneuroim.2017.10.009
Rolla, Simona, Stefania Federica De Mercanti, Valentina Bardina, Dana Horakova, Mario Habek, Ivan Adamec, Eleonora Cocco, et al. "Lack of CD4 + T cell percent decrease in alemtuzumab-treated multiple sclerosis patients with persistent relapses." Journal of Neuroimmunology 313 (2017): 89-91. https://doi.org/10.1016/j.jneuroim.2017.10.009
Rolla, S., et al. (2017) 'Lack of CD4 + T cell percent decrease in alemtuzumab-treated multiple sclerosis patients with persistent relapses', Journal of Neuroimmunology, 313, str. 89-91. doi: 10.1016/j.jneuroim.2017.10.009
Rolla S, De Mercanti SF, Bardina V, Horakova D, Habek M, Adamec I, i sur.. Lack of CD4 + T cell percent decrease in alemtuzumab-treated multiple sclerosis patients with persistent relapses. Journal of Neuroimmunology [Internet]. 15.12.2017. [pristupljeno 29.11.2024.];313:89-91. doi: 10.1016/j.jneuroim.2017.10.009
S. Rolla, et al., "Lack of CD4 + T cell percent decrease in alemtuzumab-treated multiple sclerosis patients with persistent relapses", Journal of Neuroimmunology, vol. 313, str. 89-91, Prosinac 2017. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:194192. [Citirano: 29.11.2024.]